Halozyme Therapeutics, Inc. (HALO) · Aug 18, 2026 · Exec change

Halozyme adds Appelhans to board, but filing reveals no committee assignment

Board appointment — Dannielle Appelhans elected to the Board; term ends at the 2028 annual meeting

Halozyme elected Dannielle Appelhans to its board through 2028. The routine governance move carries no disclosed strategic or financial change.

This is a routine governance appointment, not an operating update. Halozyme elected Dannielle Appelhans to its board for a term ending at the 2028 annual meeting. 〔0〕 The filing provides no transaction, strategy change, financial outlook, or shareholder-impacting action to benchmark against expectations.

The immediate signal is limited because she was not assigned to a committee. Appelhans will receive the standard non-employee director compensation available under Halozyme’s existing program, rather than a disclosed special arrangement. 〔1〕 With no background, mandate, or committee role disclosed, the filing does not establish a material change in governance or strategic direction.

Net read: neutral and informational. This is new disclosure of a board addition, but the filing offers no evidence of a beat, miss, or meaningful shift versus the company’s standing expectations.

Original filing on SEC EDGAR

More Halozyme Therapeutics, Inc. news

Halozyme adds Appelhans to board, but filing reveals no committee assignment | HALO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.